Schwartzman sergio (5 resultados)
- Tapa blanda
Librería: JR Books, Grand Rapids, MI, Estados Unidos de AmericaJR Books
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 44,48
Envío por EUR 3,88Se envía dentro de Estados Unidos de AmericaCantidad disponible: 1 disponibles
paperback. Condición: New. Fast Shipping - Safe and Secure Bubble Mailer.
- Tapa dura
Librería: Revaluation Books, Exeter, , Reino UnidoRevaluation Books
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 113,05
Envío por EUR 11,59Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 1 disponibles
Hardcover. Condición: Brand New. 9.37x6.30x0.59 inches. In Stock.
- Tapa dura
Librería: THE SAINT BOOKSTORE, Southport, , Reino UnidoTHE SAINT BOOKSTORE
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 123,60
Envío por EUR 17,21Se envía de Reino Unido a Estados Unidos de AmericaCantidad disponible: 1 disponibles
Hardback. Condición: New. New copy - Usually dispatched within 4 working days.
- Tapa dura
- Impresión bajo demanda
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, , AlemaniaBuchWeltWeit Ludwig Meier e.K.
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 108,99
Envío por EUR 23,00Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 2 disponibles
Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Guest edited by Drs. Jonathan Kay and Sergio Schwartzman, this issue of Rheumatic Disease Clinics will cover Controversies in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman o…f Cedars-Sinai. Articles explore several questions, including, but not limited to: Is triple therapy or methotrexate plus a biologic the initial treatment of choice for RA patients; Is hypo or hyper-uricemia a risk requiring treatment for cardiac morbidity and mortality; Are there benefits and risks to biosimilars from a patient perspective; Should platelet-rich plasma be used to treat osteoarthritis; Is there a role for stem cell therapy to treat cartilage defects in osteoarthritis; Should any rheumatology patient, today, be treated with bone marrow ablation and stem cell transplantation; Is there effective prevention, prophylaxis, or treatment for CPPD arthritis; Is fibromyalgia a psychiatric disease or a pain syndrome; Should cyclophosphamide still be used to treat ANCA-associated vasculitis; Does methotrexate have a place in the treatment of psoriatic arthritis; Should hydroxychloroquine dosing be limited because of potential ocular toxicity; and Should generalized immunosuppression or targeted organ treatment be the best principle for overall management of SLE. Englisch.
- Tapa dura
- Impresión bajo demanda
Librería: AHA-BUCH GmbH, Einbeck, AlemaniaAHA-BUCH GmbH
Contactar con el vendedorVendedor de 5 estrellasCondición: Nuevo
EUR 120,56
Envío por EUR 62,05Se envía de Alemania a Estados Unidos de AmericaCantidad disponible: 2 disponibles
Buch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Guest edited by Drs. Jonathan Kay and Sergio Schwartzman, this issue of Rheumatic Disease Clinics will cover Controversies in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Ced…ars-Sinai. Articles explore several questions, including, but not limited to: Is triple therapy or methotrexate plus a biologic the initial treatment of choice for RA patients; Is hypo or hyper-uricemia a risk requiring treatment for cardiac morbidity and mortality; Are there benefits and risks to biosimilars from a patient perspective; Should platelet-rich plasma be used to treat osteoarthritis; Is there a role for stem cell therapy to treat cartilage defects in osteoarthritis; Should any rheumatology patient, today, be treated with bone marrow ablation and stem cell transplantation; Is there effective prevention, prophylaxis, or treatment for CPPD arthritis; Is fibromyalgia a psychiatric disease or a pain syndrome; Should cyclophosphamide still be used to treat ANCA-associated vasculitis; Does methotrexate have a place in the treatment of psoriatic arthritis; Should hydroxychloroquine dosing be limited because of potential ocular toxicity; and Should generalized immunosuppression or targeted organ treatment be the best principle for overall management of SLE.
